A three-year follow-up of ranibizumab treatment of exudative AMD: Impact on the outcome of carrying forward the last acuity observation in drop-outs

Acta Ophthalmologica

Volumn 92, Issue 3, 2014, Pages 216-220

  Frennesson, Christina I ^a   Nilsson, Sven Erik G ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

drop outs; exudative AMD; long term results; ranibizumab treatment

Indexed keywords

RANIBIZUMAB; MONOCLONAL ANTIBODY;

AGED; ALCOHOL LIVER DISEASE; ANEMIA; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIABETIC RETINOPATHY; DRUG FATALITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMBOLISM; EPIRETINAL MEMBRANE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; INTESTINAL EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MESENTERIC BLOOD VESSEL OCCLUSION; MULTIPLE ORGAN FAILURE; OCULAR FIBROSIS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA EXUDATIVE MACULA AGE RELATED DEGENERATION; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; THROMBOEMBOLISM; TREATMENT WITHDRAWAL; VISUAL ACUITY; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA LUTEA; TIME; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84899422115     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12091     Document Type: Article

References (15)

1. Bandukwala P, Muni RH, Schwartz C, Eng KT, &, Kertes PJ, (2010): Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. Can J Ophthalmol 45: 590-595.
2. Bloch SB, la Cour M, Sander B, Hansen LK, Fuchs J, Lund-Andersen H, &, Larsen M, (2011): Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmol [Epub ahead of print].
3. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, &, Schneider S,; for the ANCHOR Study Group (2006): Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
4. Cohen SY, Dubois L, Tadavoni R, Feinkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, &, Quentel G, (2009): Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 148: 409-413.
5. Dadgostar H, Ventura AA, Chung JY, Sharma S, &, Kaiser PK, (2009): Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 116: 1740-1747.
6. Gerding H, Loukopoulos V, Riese J, Hefner L, &, Timmermann M, (2011): Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol 249: 653-662.
7. Heimes B, Lommatzsch A, Zeimer M, Gutfleisch M, Spital G, Dietzel M, &, Pauleikhoff D, (2011): Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 249: 639-644.
8. Hjelmqvist L, Lindberg C, Kanulf P, Dahlgren H, Johansson I, &, Siewert A, (2011): One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicenter study. J Ophthalmol [Epub ahead of print].
9. Holz FG, Korobelnik J-F, Lanzetta P, et al., (2010): The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model. Invest Ophthalmol Vis Sci 51: 405-412.
10. Katz G, Giavedoni L, Muni R, et al., (2012): Effectiveness at 1 year of monthly versus variable-dosing intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 32: 293-298.
11. Lala C, Framme C, Wolf-Schnurrbusch UE, &, Wolf S, (2012): Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration. Acta Ophthalmol [Epub ahead of print].
12. Michalova K, Wickremasinghe SS, Tan TH, Chang A, Harper CA, Downie JA, Hunyor AP, &, Guymer RH, (2009): Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. Eye (Lond) 23: 1633-1640.
13. Mitchell P, Korobelnik J-F, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, Tano Y, &, Wolf S, (2010): Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94: 2-13.
14. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, &, Kim RY,; for the MARINA Study Group (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.
15. Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, &, Tuomi L,; for the MARINA Study Group (2012): HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119: 1175-1183.